Deutsche Bank keeps Buy rating for Bayer stock

Published on 10/01/2026 at 14:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock costs EUR 46.61 on October 1, 2026 versus EUR 47.77. Sales rose 2.2 percent to EUR 10.872 billion in 2026's second quarter.

Flatlay auf weißem Untergrund: weiße runde Tabletten, Marmorstößel, grünes Pflanzenblatt, Glasflakon und gedrucktes DNA-Doppelhelix-Diagramm; Beschriftungskarte mit Text PHARMA — Top-down-Arrangement: weiße Tabletten, Mörser, grünes Blatt, DNA-Diagramm, Beschriftungskarte PHARMA, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) was trading at EUR 46.61 at Lang & Schwarz on October 1, 2026 at 2:36 p.m. CEST, down 2.43 percent versus the prior close of EUR 47.77. As Finanznachrichten reported on September 29, 2026, Deutsche Bank Research kept its Buy rating and EUR 60.00 price target for Bayer. The bank expects third-quarter operating sales to rise 1.30 percent year over year while operating profit falls 10.00 percent.

Q3 outlook carries two figures

The analyst view sets a demanding comparison for Bayer's next report. Sales growth of 1.30 percent would contrast with the projected 10.00 percent decline in operating profit, which Deutsche Bank Research linked to favorable agricultural effects in the prior-year period.

The report is due on November 3, 2026. That date gives the stock a clear near-term reference point because the next major test is not another annual forecast but the delivery of the third-quarter operating figures.

Second-quarter growth was positive

According to Bayer in its 2026 investor materials, second-quarter group sales increased 2.20 percent to EUR 10.872 billion, while EBITDA before special items increased 1.90 percent to EUR 2.144 billion. Crop Science supplied the stronger operating contribution, while the Pharmaceuticals division remained a key part of the earnings mix.

The company also raised financial flexibility through EUR 2.0 billion of hybrid bonds announced on September 23, 2026, as Finanznachrichten reported. The financing adds liquidity, but it also keeps leverage and capital allocation central to the Bayer investment case.

Stock remains below its yearly high

Bayer's market capitalization was EUR 45.7 billion on October 1, 2026. The Lang & Schwarz price of EUR 46.61 stood 13.56 percent below the 52-week high of EUR 53.92 and remained 80.88 percent above the 52-week low of EUR 25.78.

At EUR 60.00, the Deutsche Bank Research target lies 28.73 percent above the Lang & Schwarz price. The gap reflects the market's focus on execution: Bayer needs to convert positive Crop Science trends into group earnings while managing litigation and financing costs.

November report sets next checkpoint

Bayer lists November 3, 2026 for its third-quarter results. The combination of a 1.30 percent sales forecast and a 10.00 percent operating-profit forecast makes the report's business mix more important than the headline sales number alone.

Bayer stock was trading at EUR 46.61 at Lang & Schwarz on October 1, 2026 at 2:36 p.m. CEST, down 2.43 percent versus the Lang & Schwarz prior close of EUR 47.77. The further course of trading is shown by the continuously updated real-time quote of Bayer stock.